3SBio obtains ex-China global rights to Apexigen’s anti-TNF mAb technology 3SBio Inc., , a leading China-based biotechnology company centered on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it offers acquired the ex-China global privileges to Apexigen's anti-TNF monoclonal antibody technology silagra . 3SBio acquired the China privileges from Apexigen in 2006 previously. 3SBio's anti-TNF mAb, designated SSS07, has completed pre-clinical assessment and demonstrated higher potency compared to the best-known available TNF inhibitors, including adalimumab and infliximab, potentially improving treatment options for patients with arthritis rheumatoid and other inflammatory diseases.
According to a statement published on COPE’s site in January 2015, these attempts to hijack the scholarly review system were apparently orchestrated by agencies that initial helped authors write or improve their scientific articles and offered them favorable peer evaluations.4 BioMed Central conducted a comprehensive investigation of most their recently published content articles and identified 43 that were published based on reviews from fabricated reviewers. All these articles were retracted in March 2015. The kind of peer-review fraud committed by Moon, Chen, and third-party agencies could work when journals allow or encourage authors to suggest reviewers for his or her own submissions. Even though many editors dislike this practice, it is used frequently, for a true number of reasons. One is usually that in specific fields, authors may be best qualified to suggest suitable reviewers for the manuscript and topic involved.